Did Aptargroup beat or miss consensus estimates last quarter?

What guidance did Aptargroup's management provide for the next earnings period?

What is Aptargroup's gross profit margin?

What does Aptargroup do and what are its main business segments?

What were the key takeaways from Aptargroup’s earnings call?

What is the revenue and EPS growth rate for Aptargroup year over year?

What is Aptargroup's latest dividend and current dividend yield?

What factors drove the changes in Aptargroup's revenue and profit?

- **Revenue Resilience**: Q4 2025 sales grew 14% to $963 million, with core sales up 5% despite $65 million emergency medicine headwind.
- **Pharma Momentum**: Excluding emergency medicine, Pharma grew 10% driven by 24% injectable components and 7% prescription drug delivery systems.
- **Beauty Recovery**: 10% core sales growth in Beauty, with 1/4 from tooling, despite 220bps margin decline due to operational issues.
- **Cost Savings**: $100+ million annualized productivity improvements, with structural cost reductions across manufacturing and back-office functions.
- **Sustainability Leadership**: Ranked in CDP Climate A list and named one of America's most responsible companies for the 7th year.

**【CEO Summary Section】**
- Aptar delivered 14% reported sales growth to $963 million in Q4 2025, with core sales up 5% driven by strong demand across Pharma, Beauty, and Closures segments.
- Pharma segment (excluding emergency medicine) grew 10%, led by 24% injectable component sales and 7% prescription drug delivery systems growth.
- Beauty segment achieved 10% core sales growth, despite operational disruptions from supplier issues and environmental upgrades.
- Closures segment saw 1% core sales growth, with beverage applications up 7% and ongoing maintenance challenges in production.
- The company reaffirmed its long-term margin targets and expects sequential margin improvements in 2026.

**【CFO Financial Commentary】**
- Adjusted EBITDA of $191 million in Q4, with a 19.8% margin (down 320bps YoY) due to emergency medicine decline and segment-specific margin pressures.
- Pharma segment margin declined 330bps to 32.4% due to product mix and emergency medicine destocking.
- Beauty segment margin fell 220bps to 10.2% due to lower-margin tooling sales and operational inefficiencies.
- Closures segment margin dropped 120bps to 14.9% due to equipment maintenance and lower resin pricing pass-through.
- Full-year free cash flow of $303 million, with $486 million returned to shareholders via buybacks and dividends.
- 2026 capital expenditures expected to range between $260 million and $280 million.

**【Q&A Highlights】**
- **Pharma Growth Drivers**: Injectables (24% growth) and systemic nasal drug delivery (e.g., CARDAMYST, LTR Pharma's SPONTAN) are key growth engines, offsetting emergency medicine headwinds.
- **Beauty Segment Challenges**: Environmental upgrades and supplier fires caused $65 million of incremental costs, but expected to resolve by mid-2026.
- **Emergency Medicine Outlook**: $65 million full-year headwind (70% in H1) due to destocking and lower demand for NARCAN.
- **Sustainability Recognition**: Aptar ranked in CDP Climate A list and named one of America's most responsible companies for the 7th consecutive year.
- **Capital Allocation**: $600 million buyback authorization reflects confidence in long-term growth and balance sheet strength.

AptarGroup, Inc. (ATR) Q4 2025 Earnings Call Transcript

- **Core Growth Drivers**: Pharma pipeline (7%-11% growth) led by GLP-1, Annex 1, and biologics. Injectables capacity utilization supports 18% YoY growth.
- **Margin Differential**: Emergency medicine (35% decline) vs. high-margin pharma solutions (e.g., Unidose, SPRAVATO).
- **Balance Sheet Strength**: $265M cash, $936M net debt, $279M shareholder returns. 2025 free cash flow $624M (+8% YoY).

**【CEO Summary Section】**
- **Revenue Growth**: Q3 revenue grew 6% year-over-year, driven by 18% growth in injectables and 3% in pharma core sales. Emergency medicine sales declined 35% due to destocking, but GLP-1 and Annex 1 compliance demand offset losses.
- **Strategic Moves**: Acquired Brazilian Pharma Packaging to expand oral dosing solutions. Unidose system for edema treatment and SPRAVATO inhaler highlight innovation pipeline.
- **Margin Trends**: Adjusted EBITDA margin improved 120bps to 37.2%, supported by higher-value systems and services.

**【CFO Financial Commentary】
- **Financial Performance**: GAAP net income $420M, Non-GAAP EPS $1.62 (up 4% YoY). Free cash flow $206M, capital expenditures $386M, reflecting investment in pharma capacity and R&D.
- **Cost Management**: SG&A as % of sales declined 10bps to 15.5%. Litigation costs $4M (non-recurring) impacted net income.
- **Outlook**: Q4 adj. EPS $1.20-$1.28, driven by injectables and active materials. 2026 emergency medicine expected to decline 35% vs. 2025, but pharma pipeline (7%-11% growth) offsets.

**【Q&A Highlights】**
- **GLP-1 & Annex 1**: Injectables and elastomeric components grow 18%, aligning with biologics and compliance trends.
- **Beauty Segment**: Flat core sales due to fragrance decline, but personal care up 13%. Closures segment faces resin pricing headwinds, offset by beverage growth.
- **Shareholder Returns**: $279M returned via buybacks and dividends, with $500M authorization remaining. 2025 free cash flow $624M, up 8% YoY.
- **Risks**: Emergency medicine funding uncertainty, consumer healthcare destocking, and litigation costs ($0.06-$0.07 EPS impact).

AptarGroup, Inc. (ATR) Q3 2025 Earnings Call Transcript

- **Q2 Strong Performance**: Adjusted EPS up 18% to $1.66, driven by Pharma (+3%), Closures (+7%), and Beauty (+1%).
- **Segment Growth**: Pharma's Injectables and Active Materials offset Consumer Healthcare decline; Closures outperform industry.
- **Legal Expense Risk**: $0.06-$0.07/Q impact from IP litigation, expected for 2+ quarters.
- **Strategic Expansion**: Mod3 Pharma acquisition and BTY JV expansion enhance pharma services.
- **Share Buybacks**: $150M spent on 1M shares, total returns $210M.

**【CEO Summary Section】**
- **Q2 Results**: Adjusted EPS of $1.66, up 18% YoY, exceeding high end of guidance. Core sales growth driven by Pharma (+3%), Closures (+7%), and Beauty (+1%).
- **Segment Highlights**: Pharma's Prescription (+8%), Injectables (+9%), and Active Materials (+11%) offset Consumer Healthcare decline (-14%). Closures saw strong demand in food and beverage. Beauty resilience from Masstige fragrances and Personal Care.
- **Strategic Moves**: Acquisition of Mod3 Pharma for clinical trial manufacturing; increased ownership in BTY JV to 80%. Repurchased 1M shares ($150M) and returned $210M to shareholders.
- **Challenges**: Europe's Consumer Healthcare inventory overhang; Naloxone sales normalization amid policy uncertainty.

**【CFO Financial Commentary】**
- **Financial Metrics**: Reported sales +6% (3% core), EBITDA $218M (+13%), adjusted EPS $1.66 (+18%). Pharma EBITDA margin 35.4% (+130bps), Closures 16.9% (+130bps), Beauty 14.1% (+20bps).
- **Segment Details**: Pharma's higher-value products and services drove margin expansion. Closures benefited from innovation and cost management. Beauty's Masstige fragrances offset Prestige weakness.
- **Guidance**: Q3 EPS $1.53-$1.61, with $0.06-$0.07 impact from legal expenses. Free cash flow $92M YTD, net debt $917M, leverage 1.19x.

**【Q&A Highlights】**
- **Naloxone Concerns**: Sales growth slowing due to inventory and policy uncertainty; Injectables and Active Materials offsetting pharma headwinds.
- **Consumer Healthcare**: Europe's cold/cough season weakness; U.S. market inflection point reached.
- **Beauty Tariffs**: Prestige fragrance delays in Europe; U.S.-EU trade deal may improve visibility.
- **Legal Expenses**: $5-6M/Q expected for 2+ quarters, safeguarding IP in pharma services.

AptarGroup, Inc. (ATR) Q2 2025 Earnings Call Transcript

- **Pharma Growth**: Proprietary drug delivery systems up 4%, injectables order book robust, and SmartTrack validation study on track for Q2 2025.
- **Financial Strength**: Adjusted EBITDA of $183 million (+3% YoY), free cash flow $26 million, and $80 million share repurchases.
- **Tariff Resilience**: Local supply chain mitigates tariff risks; Beauty segment sees 30% rise in US quotation requests.
- **Q2 Guidance**: EPS $1.56-1.64, with growth across all segments despite consumer healthcare destocking.

**【CEO Summary Section】**
- **Q1 2025 Results**: Adjusted EPS of $1.20, neutralizing for currency and tax effects, showed a 5% increase YoY. Core sales for proprietary drug delivery systems grew 4%, driven by emergency medicines, CNS therapeutics, and ophthalmic treatments. Active material sales and royalties also contributed positively.
- **Pharma Segment**: 12 consecutive quarters of sales growth, with double-digit growth in six quarters. Injectables order book robust, with demand from GLP-1 and biologics. Closures segment saw product sales growth offset by lower tooling sales.
- **Beauty Segment**: Prestige fragrance sales declined, but Masstige fragrances grew double-digit. Sequential improvement in Europe and China noted. Closures segment saw 15.8% EBITDA margin improvement due to cost management.
- **Innovation & Sustainability**: Launches include nasal saline systems in Germany, ophthalmic dispensers in China, and SmartTrack clinical validation study. Named Barron's most sustainable US company for 7th year and EcoVadis Platinum rating.
- **Share Repurchases**: $80 million in Q1, reflecting confidence in future growth.

**【CFO Financial Commentary】**
- **Financial Highlights**: Adjusted EBITDA of $183 million (+3% YoY), free cash flow of $26 million. Pharma segment EBITDA margin improved 230bps to 34.8%, driven by higher-value products and cost efficiency.
- **Segment Performance**: 
  - **Pharma**: Core sales +3%, RX +10%, consumer healthcare -10% (inventory destocking). Active materials +11%.
  - **Beauty**: Core sales -3% (prestige fragrances down 11%), personal care +9%, home care +15%.
  - **Closures**: Core sales -2%, offset by tooling sales decline. Food and beverage product sales growth (+3% without tooling drag).
- **Tax Impact**: Q1 effective tax rate 25.8% vs. 20.5% YoY, due to French surtax and lower tax benefits. Q2 tax rate guided at 19-21% (midpoint 20%) with one-time benefit.
- **Liquidity**: $126 million cash, net debt $870 million, leverage ratio 1.16.

**【Q&A Key Highlights】**
- **Inventory & Demand**: US cold/cough inventory destocking nearing completion, but rest of world still elevated. Injectables demand strong, with ERP system validation delays impacting Q1.
- **Tariffs & Supply Chain**: Tariffs' net effect limited; local-for-local supply chain mitigates risks. Beauty segment sees 30% increase in US quotation requests due to tariff-related shifts.
- **Tax Rate Guidance**: Full-year ETR expected ~22-24%, excluding one-time Q2 benefit.
- **Q2 Outlook**: Adjusted EPS $1.56-1.64, driven by Pharma, Beauty, and Closures growth. Tooling activity up 30% in Beauty segment.


AptarGroup (ATR)-2 May 25-2025 Q1 Earnings call transcript

- **Q4 Strong Finish**: Core sales +2%, adjusted EPS $1.52 (27% YoY), driven by Pharma and Closure segments.
- **Pharma Dominance**: 8% core sales growth, 35% EBITDA margin, with emergency meds and CNS treatments leading.
- **Closure Recovery**: 7% Q4 growth, 16.1% EBITDA margin, benefiting from food/beverage innovation.
- **2025 Outlook**: Cautious optimism for double-digit EPS growth, excluding $0.15 Q1 headwinds from FX and tax.
- **China Green Shoots**: Local brand growth and 11/11 success suggest gradual recovery in prestige beauty.
- **Injectables Expansion**: New capacity ramping up, GLP-1 demand to drive 2025 growth.
- **Sustainability & Innovation**: Climate A List recognition, digital health app expansion, and lightweight fragrance pumps launched.


**【CEO Opening Remarks】**
- **Q4 & Full Year Performance**: Core sales grew 2% in Q4, driven by Pharma's proprietary drug delivery systems and Closure segment demand. Full-year core sales rose 3%, with Pharma leading at 8% growth.
- **Pharma Growth Drivers**: Emergency medicines, CNS therapeutics, and allergic rhinitis treatments drove Pharma's 8% core sales growth. Adjusted EBITDA margin for Pharma reached 35% for the year, up 160 basis points.
- **Closure Segment Recovery**: Closure segment returned to its long-term target range in H2, with 7% Q4 core sales growth due to food and beverage dispensing technologies. Adjusted EBITDA margin improved 260 basis points year-over-year.
- **Beauty Segment Challenges**: Beauty segment core sales declined 3% in Q4 due to prestige beauty weakness, though Personal Care and Home Care showed growth. Management expects progressive improvement in 2025.
- **Sustainability & Innovation**: Aptar secured a spot on the Climate A List and Forbes' Top Companies for Women. Digital Health app usage grew to 3 million users, and new technologies like lateral control systems and lightweight fragrance pumps were highlighted.

**【CFO Financial Details】**
- **Q4 Financials**: Adjusted EPS of $1.52 (27% YoY growth), driven by 9% increase in adjusted EBITDA to $195 million. Effective tax rate dropped to 13% due to deferred tax asset recognition.
- **Segment Breakdown**: 
  - **Pharma**: Core sales +4%, with Prescription segment up 15% and Consumer Healthcare down 17%. Adjusted EBITDA margin 35.7%, up 160 bps.
  - **Beauty**: Core sales -3%, with Fragrance/Facial Care down 9% and Personal Care +3%. Adjusted EBITDA margin 12.4%, down 230 bps due to mix shift.
  - **Closure**: Core sales +7%, driven by food (+9%) and beverage (+10%). Adjusted EBITDA margin 16.1%, up 260 bps.
- **Full-Year Cash Flow**: Operating cash flow $643 million (up 12%), free cash flow $367 million (up 40%). Debt reduced to $800 million, leverage ratio 1.08.
- **2025 Outlook**: Q1 EPS guidance $1.11-$1.19, with $0.15 headwind from currency and tax. Full-year cautious optimism for double-digit EPS growth, excluding FX and tax impacts.

**【Q&A Key Takeaways】**
- **China Recovery**: 11/11 sales and local brand growth suggest green shoots, but prestige beauty remains challenging. Management expects gradual improvement.
- **Injectables Ramp-Up**: New capacity coming online cautiously, with strong order backlog. GLP-1 and biologics growth to drive 2025 expansion.
- **Tariffs & FX**: Minimal direct impact due to regional production. Q1 FX headwind $0.07, expected to persist. French tax hike adds $0.06 Q1 EPS impact.
- **Capital Allocation**: Pharma-focused CapEx ($276 million in 2024), dividend growth (32nd consecutive year), and $0.5 billion buyback program active.
- **Beauty Restructuring**: 10 plant closures and 11% workforce reduction over 2 years. Management confident in margin improvement as top line recovers.


Actual											0.93	0.8	1	0.92	1.09	0.91	0.94	0.93	0.96	0.96	0.95	0.92	0.95	1.23	1.39	1.21	1.26	1.37	1.49	1.52	1.2	1.66	1.62	1.25
Forecast											0.8701	0.6704	0.844	0.9029	0.901	0.9654	0.94	0.91	0.9593	0.9578	0.9356	0.7899	0.9028	1.1367	1.2704	1.1171	1.146	1.3582	1.42	1.2567	1.155	1.5883	1.5671	1.2286
Surprise	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	+6.88%	+19.33%	+18.48%	+1.89%	+20.98%	-5.74%	0.00%	+2.20%	+0.07%	+0.23%	+1.54%	+16.47%	+5.23%	+8.21%	+9.41%	+8.32%	+9.95%	+0.87%	+4.93%	+20.95%	+3.90%	+4.51%	+3.38%	+1.74%

ATR

ATR fundamentals

ATR Q4 2025 Earnings

Earnings Call

You can ask Aime

ATR

ATR fundamentals

ATR Q4 2025 Earnings

Earnings Call

ATR Earnings Call Summary for Q4/20259:00 AM on Feb 6, 2026

ATR Earnings Call Summary for Q3/20259:00 AM on Oct 31, 2025

ATR Earnings Call Summary for Q2/20259:00 AM on Aug 1, 2025

ATR Earnings Call Summary for Q1/20259:00 AM on May 2, 2025

ATR Earnings Call Summary for Q4/20249:00 AM on Feb 7, 2025

You can ask Aime